HPV Vaccine Shows Lasting Protection 16 Years After Vaccination in Danish Women

This landmark Danish study provides the first long-term real-world evidence of HPV vaccine effectiveness in women who received the 4-valent vaccine as teenagers in 2008. The research matters because these women represent the first generation to reach cervical screening age after childhood vaccination, offering crucial insights for future cancer prevention strategies.

Researchers followed 8,659 women through Denmark's Trial23 screening program from 2017-2024, testing up to three consecutive cervical samples for HPV infections. The women were vaccinated at age 14 and monitored from ages 23-30, spanning their prime reproductive years when HPV infections typically occur.

The results demonstrate remarkable vaccine effectiveness: HPV16/18 infections—responsible for over 70% of cervical cancers—remained consistently below 1% across all three screening rounds in vaccinated women. This represents a dramatic reduction from pre-vaccination rates of 15-17%. The protection remained stable over time, with persistence rates of only 40% for breakthrough infections.

However, the study revealed important nuances. About one-third of vaccinated women still carried non-vaccine high-risk HPV types, and these infections were actually more common in vaccinated versus unvaccinated women. This suggests possible behavioral differences or biological compensation, though the overall cancer risk remains substantially lower.

The findings support recommendations for less intensive but continued cervical screening in vaccinated generations. Current screening protocols may be overly aggressive for these low-risk populations, potentially allowing for longer intervals between tests while maintaining safety. The research also reinforces the importance of transitioning to the 9-valent vaccine, which covers additional cancer-causing HPV types.